Article
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.
EMBO molecular medicine - 1 Jun 2018
Tsui Dana Wai Yi, Murtaza Muhammed, Wong Alvin Seng Cheong, Rueda Oscar M, Smith Christopher G, Chandrananda Dineika, Soo Ross A, Lim Hong Liang, Goh Boon Cher, Caldas Carlos, Forshew Tim, Gale Davina, Liu Wei, Morris James, Marass Francesco, Eisen Tim, Chin Tan Min, Rosenfeld Nitzan
Abstract excerpt
Tumour heterogeneity leads to the development of multiple resistance mechanisms during targeted therapies. Identifying the dominant driver(s) is critical for treatment decision. We studied the relative dynamics of multiple oncogenic drivers in longitudinal plasma of 50 EGFR-mutant non-small-cell lung cancer patients receiving gefitinib and hydroxychloroquine. We performed digital PCR and targeted sequencing on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.